Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Walker, Alison R.
- Bergua Burgues, Juan Miguel
- Bixby, Dale
- Guastad Daver, Naval
- Konopleva, Marina
- Patrick Anthony, Stephen
- Tan, Fenlai
- Chen, Yi
- Chen, Yu
- Shen, Yue
- William Burke, Patrick
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Walker,AR,Bergua,JM,Montesinos,P,Bixby,D,Guastad,N,Konopleva,M,Patrick,S et al. Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). 2022. ELECTR NETWORK-JUN 03-07. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103:LIPPINCOTT WILLIAMS & WILKINS. 2022.
Portal de investigación